Equities

Ajanta Pharma Ltd

AJANTPHARM:NSI

Ajanta Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,960.05
  • Today's Change14.55 / 0.49%
  • Shares traded57.30k
  • 1 Year change+54.26%
  • Beta0.1611
Data delayed at least 15 minutes, as of Nov 22 2024 10:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.

  • Revenue in INR (TTM)44.91bn
  • Net income in INR8.75bn
  • Incorporated1979
  • Employees7.84k
  • Location
    Ajanta Pharma LtdAjanta House,, Charkop, Kandivli West,MUMBAI 400067IndiaIND
  • Phone+91 2 266061000
  • Fax+91 2 266061200
  • Websitehttps://www.ajantapharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Neuland Laboratories Ltd.15.28bn2.80bn189.47bn1.65k67.7513.6555.1412.40217.98217.981,191.201,081.520.8472.144.859,273,565.0015.509.2520.0312.7152.1447.8118.3011.991.4031.560.07287.1330.8418.5183.5178.7617.8863.45
Wockhardt Ltd29.49bn-2.88bn190.86bn2.39k--5.31--6.47-19.85-19.85201.29221.320.3931.874.1912,318,300.00-3.93-4.56-6.33-8.2959.1055.26-10.00-12.700.56770.2470.3869--5.55-4.7317.17---4.71--
Alembic Pharmaceuticals Ltd63.57bn6.47bn204.00bn14.86k31.564.1722.063.2132.8832.88323.14248.680.9290.93665.434,278,678.009.4510.7213.3214.2573.8465.9810.1712.470.805712.620.179128.2910.199.6280.071.05-15.5914.87
Concord Biotech Ltd10.86bn3.28bn208.31bn1.38k53.7613.1054.5819.1937.0437.04114.79152.020.6551.113.557,884,886.0019.78--21.82--76.00--30.20--4.83194.730.0022--19.20--28.33------
Pfizer Ltd22.38bn6.18bn234.75bn1.72k37.996.2634.5810.49135.06135.06489.19819.900.52881.8311.1613,004,360.0014.6014.2217.0517.7165.0061.3727.6124.054.3046.210.026782.67-9.551.05-11.645.1433.359.24
Emcure Pharmaceuticals Ltd72.56bn5.67bn242.76bn11.15k42.275.8925.283.3530.3730.37389.63217.790.9781.803.966,510,068.008.027.1413.5513.9361.1159.298.207.810.95495.250.21650.0011.237.14-6.3621.35-5.93--
Natco Pharma Ltd.45.61bn19.45bn246.23bn4.02k12.663.4411.545.40108.58108.58254.65399.190.62910.89283.5711,356,080.0026.8212.3330.8514.2585.4773.0542.6325.164.19108.700.028318.9647.7213.8194.0916.59-4.7114.87
Laurus Labs Ltd50.53bn1.31bn263.73bn6.01k201.066.3848.375.222.432.4393.7076.700.6021.183.068,412,186.001.5510.132.5216.4753.4447.632.5812.830.58181.810.402313.00-16.5517.07-79.6811.3621.6821.67
J B Chemicals and Pharmaceuticals Ltd37.11bn6.11bn264.35bn5.31k44.278.2334.407.1238.4538.45233.33206.820.94812.594.856,987,882.0015.6115.7718.6218.8966.2661.1816.4716.062.2027.530.030333.0810.6316.2234.8423.3640.1537.42
Gland Pharma Ltd58.90bn6.92bn294.41bn4.22k42.573.3527.385.0041.9841.98357.57533.410.55671.284.1113,967,630.006.5413.237.6514.5660.3055.5811.7422.923.1433.110.03587.2656.2922.61-1.1011.3224.02--
Suven Pharmaceuticals Ltd9.61bn2.43bn324.43bn1.05k133.6416.40106.9333.759.549.5437.7377.710.41561.525.999,136,501.0010.5023.1711.5026.2061.4258.8525.2733.214.0029.500.019118.63-21.5622.71-26.9922.41-1.83--
Piramal Pharma Ltd87.04bn453.30m324.55bn6.72k721.714.1040.343.730.34070.340766.3659.910.57991.404.8812,954,040.000.302--0.428--63.69--0.5208--0.56037.490.3771--15.39--109.56------
Ajanta Pharma Ltd44.91bn8.75bn367.93bn7.84k42.3510.0136.368.1969.5569.55356.94294.360.97381.334.165,725,128.0018.9716.6123.2920.4775.7773.2219.4819.312.1349.880.008831.2012.4515.4138.8116.10-14.9710.76
IPCA Laboratories Ltd85.33bn6.61bn399.22bn17.34k60.375.9637.424.6826.0726.07336.37264.100.74831.124.784,922,642.005.8810.339.0013.5267.3659.167.8512.251.3225.330.12912.8623.3915.3516.134.2417.9021.67
GlaxoSmithKline Pharmaceuticals Limited35.60bn6.75bn401.43bn3.21k59.8424.0053.9911.2739.6039.60209.3198.741.012.5914.8511,088,370.0019.2411.0136.0917.8861.7055.7718.9612.251.38554.800.0088192.076.212.00-2.915.78-36.029.86
Glenmark Pharmaceuticals Ltd122.48bn-10.18bn413.80bn14.99k--4.90--3.38-36.13-31.05434.11299.290.69511.534.048,171,082.00-5.641.02-8.511.4365.6459.47-8.111.431.002.560.174156.981.983.67-1,018.93---5.894.56
Data as of Nov 22 2024. Currency figures normalised to Ajanta Pharma Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

14.25%Per cent of shares held by top holders
HolderShares% Held
UTI Asset Management Co. Ltd. (Investment Management)as of 31 Oct 20243.85m3.09%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 20243.73m2.98%
The Vanguard Group, Inc.as of 06 Nov 20241.60m1.28%
Kotak Mahindra Asset Management Co. Ltd.as of 31 Oct 20241.55m1.24%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Oct 20241.38m1.11%
Canara Robeco Asset Management Co. Ltd.as of 31 Oct 20241.28m1.03%
White Oak Capital Partners Pte Ltd.as of 30 Jun 20231.18m0.95%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Oct 20241.18m0.94%
Tata AIA Life Insurance Co. Ltd.as of 31 Oct 20241.09m0.87%
Invesco Asset Management (India) Pvt Ltd.as of 31 Oct 2024961.66k0.77%
More ▼
Data from 30 Jun 2023 - 14 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.